An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Brendon Stiles, MD
Montefiore Medical Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Washington University in St. Louis
St Louis, Missouri, United States
- Montefiore Medical Center-Albert Einstein College of Medicine
The Bronx, New York, United States
- White Plains Hospital (wph)
White Plains, New York, United States
- Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 25 Jan 2023
- Primary completion
- 1 Jul 2025
- Completion
- 31 May 2030
- Last update posted
- 28 Jan 2026
- Registered enrollment
- 17
- Registry id
- NCT05500092
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.